The promise of cardiovascular biomarkers in assessing children with cardiac disease and in predicting cardiovascular events in adults

Progress in Pediatric Cardiology

Volumn 32, Issue 1, 2011, Pages 25-34

  Wilkinson, James D ^a   Diamond, Melissa ^a   Miller, Tracie L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Biomarkers; Cardiomyopathy; Child; Congenital heart disease; Heart failure

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; GELATINASE A; GELATINASE B; GHRELIN; GROWTH HORMONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRILYSIN; NEUTROPHIL COLLAGENASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NITROGEN; PIPERANOMETOZINE; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UREA;

ACUTE GRAFT REJECTION; ADULT; ADVERSE OUTCOME; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOPULMONARY BYPASS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD CANCER; CONGENITAL HEART DISEASE; CYTOKINE RELEASE; DYSPNEA; ENDOTHELIAL DYSFUNCTION; GLUCOSE METABOLISM; GREAT VESSELS TRANSPOSITION; GROWTH HORMONE DEFICIENCY; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART TRANSPLANTATION; HORMONAL THERAPY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPOPLASTIC LEFT HEART SYNDROME; HYPOXIA; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SHORT STATURE; SYSTOLIC DYSFUNCTION; UREA NITROGEN BLOOD LEVEL;

EID: 79961171435     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2011.06.006     Document Type: Article

References (159)

1. de Couto G., Ouzounian M., Liu P.P. Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol 2010, 7:334-344.
2. Lipshultz S.E. Ventricular dysfunction clinical research in infants, children and adolescents. Prog Pediatr Cardiol 2000, 12:1-28.
3. Schwartz M.L., Cox G.F., Lin A.E., et al. Clinical approach to genetic cardiomyopathy in children. Circulation 1996, 94:2021-2038.
4. Kumar K., Thatai D., Saxena A., et al. Pediatric dilated cardiomyopathy (DCM): prognosis in a developing nation is comparable to developed nations. J Am Coll Cardiol 1996, 27:187A.
5. Bilgic A., Ozbarlas N., Ozkutlu S., Ozer S., Ozme S. Cardiomyopathies in children. Clinical, epidemiological and prognostic evaluation. Jpn Heart J 1990, 31:789-797.
6. Boucek M.M., Faro A., Novick R.J., et al. The registry of the international society for heart and lung transplantation: fourth official pediatric report-2000. J Heart Lung Transplant 2001, 20:39-52.
7. Bozkurt B., Mann D.L., Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev 2010, 15:331-341.
8. Smith S.C., Anderson J.L., Cannon R.O., et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the clinical practice discussion group. Circulation 2004, 110:e550-e553.
9. Foster S.B., Reuben J., Cohen E., et al. Circadian regulation of IL-6, IL1beta and IL-1RA level is disrupted in HIV-infected children. Clin Immunol 2009, 131:S55.
10. Torre-Amione G., Kapadia S., Lee J., et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995, 92:1487-1493.
11. Pincott E.S., Burch M. New biomarkers in heart failure. Prog Pediatr Cardiol 2011, 31:49-52.
12. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
13. Ferrari R., Hearse D.J. Surrogate end points in heart failure trials: potential and limitations. Dialog Cardiovasc Med 2010, 1:79-171.
14. Stein P.K., Barzilay J.I., Chaves P.H., et al. Higher levels of inflammation factors and greater insulin resistance are independently associated with higher heart rate and lower heart rate variability in normoglycemic older individuals: the Cardiovascular Health Study. J Am Geriatr Soc 2008, 56:315-321.
15. Hlatky M.A., Ashley E., Quertermous T., et al. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J 2007, 154:1043-1051.
16. Arruda-Olson A.M., Enriquez-Sarano M., Bursi F., et al. Left ventricular function and C-reactive protein levels in acute myocardial infarction. Am J Cardiol 2010, 105:917-921.
17. Dunlay S.M., Gerber Y., Weston S.A., et al. Prognostic value of biomarkers in heart failure: application of novel methods in the community. Circ Heart Fail 2009, 2:393-400.
18. Velagaleti R.S., Gona P., Sundstrom J., et al. Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality. Arterioscler Thromb Vasc Biol 2010, 30:2283-2288.
19. Schnabel R.B., Larson M.G., Yamamoto J.F., et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009, 104:92-96.
20. Joseph J., Pencina M.J., Wang T.J., et al. Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. J Hypertens 2009, 27:1317-1324.
21. Broeckel U., Hengstenberg C., Mayer B., et al. A locus on chromosome 10 influences C-reactive protein levels in two independent populations. Hum Genet 2007, 122:95-102.
22. Yan A.T., Yan R.T., Cushman M., et al. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J 2010, 31:875-882.
23. Carty C.L., Heagerty P., Heckbert S.R., et al. Interaction between fibrinogen and IL-6 genetic variants and associations with cardiovascular disease risk in the Cardiovascular Health Study. Ann Hum Genet 2010, 74:1-10.
24. Cushman M., McClure L.A., Howard V.J., et al. Implications of increased C-reactive protein for cardiovascular risk stratification in black and white men and women in the US. Clin Chem 2009, 55:1627-1636.
25. Jenny N.S., Brown E.R., Detrano R., et al. Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2010, 209:226-229.
26. Xun P., Liu K., Morris J.S., et al. Associations of toenail selenium levels with inflammatory biomarkers of fibrinogen, high-sensitivity c-reactive protein, and interleukin-6: The CARDIA Trace Element Study. Am J Epidemiol 2010, 171:793-800.
27. Thompson A.M., Zhang Y., Tong W., et al. Association of obesity and biomarkers of inflammation and endothelial dysfunction in adults in Inner Mongolia, China. Int J Cardiol 2010, 10.1016/j.ijcard.2010.04.011.
28. Itakura H., Sobel B.E., Boothroyd D., et al. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?. Am Heart J 2007, 154:1059-1064.
29. Neuhaus J., Jacobs D.R., Baker J.V., et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010, 201:1788-1795.
30. Bowden D.W., Lange L.A., Langefeld C.D., et al. The relationship between C-reactive protein and subclinical cardiovascular disease in the Diabetes Heart Study (DHS). Am Heart J 2005, 150:1032-1038.
31. Pischon T., Hu F.B., Rexrode K.M., et al. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 2008, 197:392-399.
32. Pannu H., Kim D.H., Guo D., et al. The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms. J Neurosurg 2006, 105:418-423.
33. Enquobahrie D.A., Rice K., Williams O.D., et al. IL1B genetic variation and plasma C-reactive protein level among young adults: the CARDIA study. Atherosclerosis 2009, 202:513-520.
34. Dunlay S.M., Weston S.A., Redfield M.M., Killian J.M., Roger V.L. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation 2008, 118:625-631.
35. Boerrigter G., Burnett J.C. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 2004, 13:643-652.
36. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003, 24:341-356.
37. Nakagawa O., Ogawa Y., Itoh H., et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995, 96:1280-1287.
38. Hama N., Itoh H., Shirakami G., et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995, 92:1558-1564.
39. Lim P., Monin J.L., Monchi M., et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 2004, 25:2048-2053.
40. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004, 109:3176-3181.
41. Niinuma H., Nakamura M., Hiramori K. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Cardiology 1998, 90:89-94.
42. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997, 350:1349-1353.
43. Richards A.M., Doughty R., Nicholls M.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001, 37:1781-1787.
44. Koglin J., Pehlivanli S., Schwaiblmair M., et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001, 38:1934-1941.
45. Ohuchi H., Takasugi H., Ohashi H., et al. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation 2003, 108:2368-2376.
46. Price J.F., Mott A.R., Dickerson H.A., et al. Worsening renal function in children hospitalized with decompensated heart failure: evidence for a pediatric cardiorenal syndrome?. Pediatr Crit Care Med 2008, 9:279-284.
47. Ratnasamy C., Kinnamon D.D., Lipshultz S.E., Rusconi P. Associations between neurohormonal and inflammatory activation and heart failure in children. Am Heart J 2008, 155:527-533.
48. Mangat J., Carter C., Riley G., Foo Y., Burch M. The clinical utility of brain natriuretic peptide in paediatric left ventricular failure. Eur J Heart Fail 2009, 11:48-52.
49. Lin N.C., Landt M.L., Trinkaus K.M., et al. Relation of age, severity of illness, and hemodynamics with brain natriuretic peptide levels in patients <20years of age with heart disease. Am J Cardiol 2005, 96:847-850.
50. Auerbach S.R., Richmond M.E., Lamour J.M., et al. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial. Circ Heart Fail 2010, 3:606-611.
51. Anderson P.A., Sleeper L.A., Mahony L., et al. Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. J Am Coll Cardiol 2008, 52:85-98.
52. Williams I.A., Sleeper L.A., Colan S.D., et al. Functional state following the Fontan procedure. Cardiol Young 2009, 19:320-330.
53. Lipshultz S.E., Lipsitz S.R., Scully R.E., et al. N-terminal pro-brain natriuretic peptide-defined cardiomyopathy in doxorubicin-treated children with acute lymphoblastic leukemia. Circulation 2007, 116:II-563.
54. Yoshibayashi M., Kamiya T., Saito Y., et al. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol 1995, 133:207-209.
55. Nir A., Lindinger A., Rauh M., et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009, 30:3-8.
56. Tan L.H., Jefferies J.L., Liang J.F., et al. Concentrations of brain natriuretic peptide in the plasma predicts outcomes of treatment of children with decompensated heart failure admitted to the Intensive Care unit. Cardiol Young 2007, 17:397-406.
57. Mir T.S., Marohn S., Laer S., et al. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002, 110:e76.
58. Koch A., Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003, 89:875-878.
59. Cantinotti M., Storti S., Ripoli A., et al. Diagnostic accuracy of B-type natriuretic hormone for congenital heart disease in the first month of life. Clin Chem Lab Med 2010, 48:1333-1338.
60. Shah A., Feraco A.M., Harmon C., et al. Usefulness of various plasma biomarkers for diagnosis of heart failure in children with single ventricle physiology. Am J Cardiol 2009, 104:1280-1284.
61. Eerola A., Jokinen E., Boldt T., Mattila I.P., Pihkala J.I. Serum levels of natriuretic peptides in children before and after treatment for an atrial septal defect, a patent ductus arteriosus, and a coarctation of the aorta-a prospective study. Int J Pediatr 2010, 2010:674575.
62. Perez-Piaya M., Abarca E., Soler V., et al. Levels of N-terminal-pro-brain natriuretic peptide in congenital heart disease surgery and its value as a predictive biomarker. Interact Cardiovasc Thorac Surg 2011, 12:461-466.
63. Rossano J.W., Denfield S.W., Kim J.J., et al. B-type natriuretic peptide is a sensitive screening test for acute rejection in pediatric heart transplant patients. J Heart Lung Transplant 2008, 27:649-654.
64. Talha S., Charloux A., Enache I., Piquard F., Geny B. Mechanisms involved in increased plasma brain natriuretic peptide after heart transplantation. Cardiovasc Res 2011, 89:273-281.
65. Deswal A., Petersen N.J., Feldman A.M., et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103:2055-2059.
66. Higuchi Y., McTiernan C.F., Frye C.B., et al. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation 2004, 109:1892-1897.
67. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107:1486-1491.
68. Frangogiannis N.G., Lindsey M.L., Michael L.H., et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation 1998, 98:699-710.
69. Aukrust P., Ueland T., Lien E., et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999, 83:376-382.
70. Yilmaz E., Ustundag B., Sen Y., et al. The levels of Ghrelin, TNF-alpha, and IL-6 in children with cyanotic and acyanotic congenital heart disease. Mediators Inflamm 2007, 2007:32403.
71. Miller B.E., Levy J.H. The inflammatory response to cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997, 11:355-366.
72. Butler J., Rocker G.M., Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993, 55:552-559.
73. Wan S., LeClerc J.L., Vincent J.L. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997, 112:676-692.
74. Appachi E., Mossad E., Mee R.B., Bokesch P. Perioperative serum interleukins in neonates with hypoplastic left-heart syndrome and transposition of the great arteries. J Cardiothorac Vasc Anesth 2007, 21:184-190.
75. Steinberg J.B., Kapelanski D.P., Olson J.D., Weiler J.M. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993, 106:1008-1016.
76. Hauser G.J., Ben-Ari J., Colvin M.P., et al. Interleukin-6 levels in serum and lung lavage fluid of children undergoing open heart surgery correlate with postoperative morbidity. Intensive Care Med 1998, 24:481-486.
77. Hovels-Gurich H.H., Schumacher K., Vazquez-Jimenez J.F., et al. Cytokine balance in infants undergoing cardiac operation. Ann Thorac Surg 2002, 73:601-608. discussion 8-9.
78. Silveira R.C., Procianoy R.S. Interleukin-6 and tumor necrosis factor-alpha levels in plasma and cerebrospinal fluid of term newborn infants with hypoxic-ischemic encephalopathy. J Pediatr 2003, 143:625-629.
79. McQuinn T.C., Deardorff R.L., Mukherjee R., et al. Circulating matrix metalloproteinase levels after ventricular septal defect repair in infants. J Thorac Cardiovasc Surg 2010, 140:1257-1265.
80. Kozik D.J., Tweddell J.S. Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2006, 81:S2347-S2354.
81. Brix-Christensen V. The systemic inflammatory response after cardiac surgery with cardiopulmonary bypass in children. Acta Anaesthesiol Scand 2001, 45:671-679.
82. Pye M., Rae A.P., Cobbe S.M. Study of serum C-reactive protein concentration in cardiac failure. Br Heart J 1990, 63:228-230.
83. Kaneko K., Kanda T., Hasegawa A., et al. C-reactive protein as a prognostic marker in lymphocytic myocarditis. Jpn Heart J 2000, 41:41-47.
84. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108:2317-2322.
85. Tomita H., Takamuro M., Soda W., Hatakeyama K., Tsutsumi H. Increased serum high-sensitivity C-reactive protein is related to hypoxia and brain natriuretic peptide in congenital heart disease. Pediatr Int 2008, 50:436-440.
86. Colan S.D., Lipshultz S.E., Lowe A.M., et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007, 115:773-781.
87. Decker J.A., Rossano J.W., Smith E.O., et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol 2009, 54:250-254.
88. Ostman-Smith I., Wettrell G., Keeton B., et al. Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur Heart J 2008, 29:1160-1167.
89. Gajarski R., Naftel D.C., Pahl E., et al. Outcomes of pediatric patients with hypertrophic cardiomyopathy listed for transplant. J Heart Lung Transplant 2009, 28:1329-1334.
90. Shirani J., Pick R., Roberts W.C., Maron B.J. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000, 35:36-44.
91. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-573.
92. Brower G.L., Gardner J.D., Forman M.F., et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006, 30:604-610.
93. Lombardi R., Betocchi S., Losi M.A., et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 2003, 108:1455-1460.
94. Noji Y., Shimizu M., Ino H., et al. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 2004, 68:355-360.
95. Fassbach M., Schwartzkopff B. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol 2005, 94:328-335.
96. Roldan V., Marin F., Gimeno J.R., et al. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J 2008, 156:85-91.
97. Moon J.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 43:2260-2264.
98. Joffe A.R., Schulz C., Rosychuk R.J., et al. Plasma matrix metalloproteinases in neonates having surgery for congenital heart disease. Heart Int 2009, 4:14-19.
99. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
100. Dasu M.R., Spies M., Barrow R.E., Herndon D.N. Matrix metalloproteinases and their tissue inhibitors in severely burned children. Wound Repair Regen 2003, 11:177-180.
101. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., Stevenson L.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000, 35:681-689.
102. Hillege H.L., Girbes A.R., de Kam P.J., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000, 102:203-210.
103. Al-Ahmad A., Sarnak M.J., Salem D.N., Konstam M.A. Cause and management of heart failure in patients with chronic renal disease. Semin Nephrol 2001, 21:3-12.
104. Hillege H.L., Nitsch D., Pfeffer M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113:671-678.
105. Ronco C., Haapio M., House A.A., Anavekar N., Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008, 52:1527-1539.
106. Lipshultz S.E., Somers M.L.G., Lipsitz S.R., et al. Relation between serum troponin levels and cardiovascular status in children and young adults with chronic renal failure. Pediatr Res 1999, 45:26A.
107. Zhang K., Shaw M., Keenan J., et al. Changes in the renal expression of RPA-1, RPA-2, and KIM-1 from spontaneously hypertensive rates (SHR) given doxorubicin (DXR) or mitroxantrone (MTX), with or without dexrazoxane (DRZ). Toxicologist 2007, 102:A456.
108. Mishra J., Ma Q., Prada A., et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003, 14:2534-2543.
109. Devarajan P. Neutrophil gelatinase-associated lipocalin - an emerging troponin for kidney injury. Nephrol Dial Transplant 2008, 23:3737-3743.
110. Bolignano D., Basile G., Parisi P., et al. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res 2009, 12:7-14.
111. Villa P., Jimenez M., Soriano M.C., Manzanares J., Casasnovas P. Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients. Crit Care 2005, 9:R139-R143.
112. Delanaye P., Lambermont B., Chapelle J.P., et al. Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units. Intensive Care Med 2004, 30:980-983.
113. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007, 356:1140-1151.
114. Nikolaidis L.A., Elahi D., Hentosz T., et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961.
115. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694-699.
116. Swan J.W., Anker S.D., Walton C., et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997, 30:527-532.
117. Goode K.M., John J., Rigby A.S., et al. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart 2009, 95:917-923.
118. Ohuchi H., Miyamoto Y., Yamamoto M., et al. High prevalence of abnormal glucose metabolism in young adult patients with complex congenital heart disease. Am Heart J 2009, 158:30-39.
119. Hruz P.W., Yan Q., Struthers H., Jay P.Y. HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy. FASEB J 2008, 22:2161-2167.
120. Yang K.C., Yan Q.Y., Jay P.Y., Hruz P.W. Rosiglitazone and exenatide improve survival in a murine model of dilated cardiomyopathy. Diabetes 2008, 57:A4-A5.
121. Nakazato M., Murakami N., Date Y., et al. A role for ghrelin in the central regulation of feeding. Nature 2001, 409:194-198.
122. Park H.S., Lee K.U., Kim Y.S., Park C.Y. Relationships between fasting plasma ghrelin levels and metabolic parameters in children and adolescents. Metabolism 2005, 54:925-929.
123. Nagaya N., Kojima M., Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. Intern Med 2006, 45:127-134.
124. Kandil M.E., Elwan A., Hussein Y., Kandeel W., Rasheed M. Ghrelin levels in children with congenital heart disease. J Trop Pediatr 2009, 55:307-312.
125. Lipshultz S.E., Vlach S.A., Lipsitz S.R., et al. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 2005, 115:1613-1622.
126. Miller T.L., Lipsitz S.R., Lopez-Mitnik G., et al. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 2010, 19:2013-2022.
127. Noordam C. Growth hormone and the heart in Noonan syndrome. Horm Res 2009, 72(Suppl 2):49-51.
128. Cotterill A.M., McKenna W.J., Brady A.F., et al. The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome. J Clin Endocrinol Metab 1996, 81:2291-2297.
129. Dinleyici E.C., Kilic Z., Buyukkaragoz B., et al. Serum IGF-1, IGFBP-3 and growth hormone levels in children with congenital heart disease: relationship with nutritional status, cyanosis and left ventricular functions. Neuro Endocrinol Lett 2007, 28:279-283.
130. Dundar B., Akcoral A., Saylam G., et al. Chronic hypoxemia leads to reduced serum IGF-I levels in cyanotic congenital heart disease. J Pediatr Endocrinol Metab 2000, 13:431-436.
131. Pervanidou P., Margeli A., Akalestos A., et al. Associations between circulating N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) and adiponectin concentrations depend on obesity level in female adolescents: gender dimorphic findings. Horm Metab Res 2009, 41:829-833.
132. Arnaiz P., Acevedo M., Barja S., et al. Adiponectin levels, cardiometabolic risk factors and markers of subclinical atherosclerosis in children. Int J Cardiol 2010, 138:138-144.
133. Kanani P.M., Sinkey C.A., Browning R.L., et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999, 100:1161-1168.
134. Ungvari Z., Gupte S.A., Recchia F.A., Batkai S., Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 2005, 3:221-229.
135. Grieve D.J., Shah A.M. Oxidative stress in heart failure. More than just damage. Eur Heart J 2003, 24:2161-2163.
136. Kameda K., Matsunaga T., Abe N., et al. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 2003, 24:2180-2185.
137. Hokamaki J., Kawano H., Yoshimura M., et al. Urinary biopyrrins levels are elevated in relation to severity of heart failure. J Am Coll Cardiol 2004, 43:1880-1885.
138. Polidori M.C., Pratico D., Savino K., et al. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J Card Fail 2004, 10:334-338.
139. Tang W.H., Brennan M.L., Philip K., et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 2006, 98:796-799.
140. Developmental origins of health and disease 2006, Cambridge University Press, New York. P.D. Gluckman, M.A. Hanson (Eds.).
141. A life course approach to chronic disease epidemiology 2004, Oxford University Press, New York. 2nd ed. D. Kuh, Y. Ben-Schlomo (Eds.).
142. McMahan C.A., Gidding S.S., Fayad Z.A., et al. Risk scores predict atherosclerotic lesions in young people. Arch Intern Med 2005, 165:883-890.
143. McMahan C.A., Gidding S.S., Malcom G.T., et al. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics 2006, 118:1447-1455.
144. Gidding S.S., McMahan C.A., McGill H.C., et al. Prediction of coronary artery calcium in young adults using the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) risk score: the CARDIA study. Arch Intern Med 2006, 166:2341-2347.
145. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
146. Calara F., Dimayuga P., Niemann A., et al. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 1998, 18:884-893.
147. Dichtl W., Nilsson L., Goncalves I., et al. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 1999, 84:1085-1094.
148. Wilson S.H., Caplice N.M., Simari R.D., et al. Activated nuclear factor-kappaB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis 2000, 148:23-30.
149. Collins T., Cybulsky M.I. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 2001, 107:255-264.
150. Li H., Cybulsky M.I., Gimbrone M.A., Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993, 13:197-204.
151. Rosenfeld M.E., Yla-Herttuala S., Lipton B.A., et al. Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am J Pathol 1992, 140:291-300.
152. Clinton S.K., Underwood R., Hayes L., et al. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol 1992, 140:301-316.
153. Fisher S.D., Miller T.L., Lipshultz S.E. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis 2006, 185:1-11.
154. Mann J., Davies M.J. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999, 82:265-268.
155. Amento E.P., Ehsani N., Palmer H., Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991, 11:1223-1230.
156. Falk E. Why do plaques rupture?. Circulation 1992, 86:III30-III42.
157. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
158. Sukhova G.K., Schonbeck U., Rabkin E., et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999, 99:2503-2509.
159. Herman M.P., Sukhova G.K., Libby P., et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001, 104:1899-1904.